NSAID effect on sporadic colon polyps

L. J. Hixson, D. L. Earnest, M (Brian) Fennerty, R. E. Sampliner

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

In this study, our objective was to determine whether 6 months of open- label therapy with sulindac 400 mg/daily or piroxicam 20 mg/daily promote regression of adenomatous colonic polyps left in situ. Left-sided colonic polyps (size 3-12 mm) detected at colonoscopy were measured and left without being biopsied. The bowel wall opposite to the polyps was marked with India ink submucosally. Patients were assigned to drug therapy, and compliance was determined by pill count. Polyps were measured during sigmoidoscopy after 3 and 6 months of treatment; polyps were removed at the 6-month examination. Examiners were not blinded to drug therapy or previous polyp measurements. Seven patients completed 6 months of therapy (five sulindac and two piroxicam). Two additional patients treated with piroxicam were withdrawn secondary to adverse events (bleeding gastric ulcer and rash). In one patient treated with sulindac, a 6-mm polyp disappeared, and two other polyps seemed to regress partially. One polyp regressed partially in a piroxicam-treated patient. All other polyps remained unchanged. Conclusions: We did not observe dramatic regression of sporadic colon adenomatous polyps to either sulindac or piroxicam after 6 months of therapy in this small uncontrolled pilot study.

Original languageEnglish (US)
Pages (from-to)1652-1656
Number of pages5
JournalAmerican Journal of Gastroenterology
Volume88
Issue number10
StatePublished - 1993
Externally publishedYes

Fingerprint

Non-Steroidal Anti-Inflammatory Agents
Polyps
Colon
Piroxicam
Sulindac
Colonic Polyps
Adenomatous Polyps
Sigmoidoscopy
Drug Therapy
Colonoscopy
Stomach Ulcer
Therapeutics
Exanthema
Compliance
Hemorrhage

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Hixson, L. J., Earnest, D. L., Fennerty, M. B., & Sampliner, R. E. (1993). NSAID effect on sporadic colon polyps. American Journal of Gastroenterology, 88(10), 1652-1656.

NSAID effect on sporadic colon polyps. / Hixson, L. J.; Earnest, D. L.; Fennerty, M (Brian); Sampliner, R. E.

In: American Journal of Gastroenterology, Vol. 88, No. 10, 1993, p. 1652-1656.

Research output: Contribution to journalArticle

Hixson, LJ, Earnest, DL, Fennerty, MB & Sampliner, RE 1993, 'NSAID effect on sporadic colon polyps', American Journal of Gastroenterology, vol. 88, no. 10, pp. 1652-1656.
Hixson LJ, Earnest DL, Fennerty MB, Sampliner RE. NSAID effect on sporadic colon polyps. American Journal of Gastroenterology. 1993;88(10):1652-1656.
Hixson, L. J. ; Earnest, D. L. ; Fennerty, M (Brian) ; Sampliner, R. E. / NSAID effect on sporadic colon polyps. In: American Journal of Gastroenterology. 1993 ; Vol. 88, No. 10. pp. 1652-1656.
@article{6e2150487f8e4d03a91bc7d94f398fa0,
title = "NSAID effect on sporadic colon polyps",
abstract = "In this study, our objective was to determine whether 6 months of open- label therapy with sulindac 400 mg/daily or piroxicam 20 mg/daily promote regression of adenomatous colonic polyps left in situ. Left-sided colonic polyps (size 3-12 mm) detected at colonoscopy were measured and left without being biopsied. The bowel wall opposite to the polyps was marked with India ink submucosally. Patients were assigned to drug therapy, and compliance was determined by pill count. Polyps were measured during sigmoidoscopy after 3 and 6 months of treatment; polyps were removed at the 6-month examination. Examiners were not blinded to drug therapy or previous polyp measurements. Seven patients completed 6 months of therapy (five sulindac and two piroxicam). Two additional patients treated with piroxicam were withdrawn secondary to adverse events (bleeding gastric ulcer and rash). In one patient treated with sulindac, a 6-mm polyp disappeared, and two other polyps seemed to regress partially. One polyp regressed partially in a piroxicam-treated patient. All other polyps remained unchanged. Conclusions: We did not observe dramatic regression of sporadic colon adenomatous polyps to either sulindac or piroxicam after 6 months of therapy in this small uncontrolled pilot study.",
author = "Hixson, {L. J.} and Earnest, {D. L.} and Fennerty, {M (Brian)} and Sampliner, {R. E.}",
year = "1993",
language = "English (US)",
volume = "88",
pages = "1652--1656",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - NSAID effect on sporadic colon polyps

AU - Hixson, L. J.

AU - Earnest, D. L.

AU - Fennerty, M (Brian)

AU - Sampliner, R. E.

PY - 1993

Y1 - 1993

N2 - In this study, our objective was to determine whether 6 months of open- label therapy with sulindac 400 mg/daily or piroxicam 20 mg/daily promote regression of adenomatous colonic polyps left in situ. Left-sided colonic polyps (size 3-12 mm) detected at colonoscopy were measured and left without being biopsied. The bowel wall opposite to the polyps was marked with India ink submucosally. Patients were assigned to drug therapy, and compliance was determined by pill count. Polyps were measured during sigmoidoscopy after 3 and 6 months of treatment; polyps were removed at the 6-month examination. Examiners were not blinded to drug therapy or previous polyp measurements. Seven patients completed 6 months of therapy (five sulindac and two piroxicam). Two additional patients treated with piroxicam were withdrawn secondary to adverse events (bleeding gastric ulcer and rash). In one patient treated with sulindac, a 6-mm polyp disappeared, and two other polyps seemed to regress partially. One polyp regressed partially in a piroxicam-treated patient. All other polyps remained unchanged. Conclusions: We did not observe dramatic regression of sporadic colon adenomatous polyps to either sulindac or piroxicam after 6 months of therapy in this small uncontrolled pilot study.

AB - In this study, our objective was to determine whether 6 months of open- label therapy with sulindac 400 mg/daily or piroxicam 20 mg/daily promote regression of adenomatous colonic polyps left in situ. Left-sided colonic polyps (size 3-12 mm) detected at colonoscopy were measured and left without being biopsied. The bowel wall opposite to the polyps was marked with India ink submucosally. Patients were assigned to drug therapy, and compliance was determined by pill count. Polyps were measured during sigmoidoscopy after 3 and 6 months of treatment; polyps were removed at the 6-month examination. Examiners were not blinded to drug therapy or previous polyp measurements. Seven patients completed 6 months of therapy (five sulindac and two piroxicam). Two additional patients treated with piroxicam were withdrawn secondary to adverse events (bleeding gastric ulcer and rash). In one patient treated with sulindac, a 6-mm polyp disappeared, and two other polyps seemed to regress partially. One polyp regressed partially in a piroxicam-treated patient. All other polyps remained unchanged. Conclusions: We did not observe dramatic regression of sporadic colon adenomatous polyps to either sulindac or piroxicam after 6 months of therapy in this small uncontrolled pilot study.

UR - http://www.scopus.com/inward/record.url?scp=0027364328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027364328&partnerID=8YFLogxK

M3 - Article

C2 - 8213705

AN - SCOPUS:0027364328

VL - 88

SP - 1652

EP - 1656

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 10

ER -